Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus

Overview

This study will assess the safety and efficacy of KRP203 in clinically active subacute cutaneous lupus erythematosus patients, who have demonstrated inadequate response to standard treatment, such as antimalarials.

Full Title of Study: “A Multi-center, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy and Tolerability of KRP203 in Patients With Active Subacute Cutaneous Lupus Erythematosus”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: October 2012

Interventions

  • Drug: KRP203 – 1.2mg
  • Drug: Placebo to KRP203 – 1.2 mg

Arms, Groups and Cohorts

  • Experimental: KRP203 – 1.2 mg
  • Placebo Comparator: Placebo to KRP203 – 1.2 mg

Clinical Trial Outcome Measures

Primary Measures

  • Efficacy of KRP203 in reduction of severity of symptoms, as measured using the activity score of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)
    • Time Frame: 12 weeks

Secondary Measures

  • Safety and tolerability of oral KRP203 in patients with subacute cutaneous lupus erythematosus
    • Time Frame: 12 weeks
  • Steady-state blood concentrations of KRP203 and KRP203-Phosphate (KRP203-P) in SCLE patients
    • Time Frame: 12 weeks
  • Changes in the activity of SCLE using visual analogue scales for global skin health as assessed by the physician and the patient
    • Time Frame: 12 weeks
  • Measure the systemic features of SCLE using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
    • Time Frame: 12 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • Male and female patients,18 to 65 years of age inclusive, who have been defined as having SCLE based on the typical clinical picture and the characteristic histopathological features as described by Sontheimer et al. at least three months before study entry (screening) Exclusion Criteria:

1. Patients with preexisting nephritis, central nervous or pulmonary involvement or any major internal organ damage, either related or unrelated to lupus, which are deemed by the Investigator to be clinically significant. Patients having signs or symptoms of other autoimmune diseases such as systemic lupus erythematosus or Sjogren's syndrome are allowed to enter the study at the Investigator's discretion. 2. Patients who have been treated with:

  • immunoglobulins and/or monoclonal antibodies within 6 months prior to randomization. – rituximab, cyclophosphamide, or other immunosuppressive treatments with effects potentially lasting over 6 months, within 12 months prior to randomization. – a medium or high dose (≥ 1 mg prednisone or equivalent per body weight kg) corticosteroid therapy in the last 8 weeks prior to randomization. – antimalarial agents (hydroxychloroquine, chloroquine or quinacrine) in the last 6 weeks prior to randomization. – biologic therapies, such as etanercept, within the last 4 weeks prior to randomization. – any other immunosuppressive or immunomodulatory therapy such as methotrexate, azathioprine, cyclosporin A or mycophenolate, thalidomide, retinoids or dapsone in the last 4 weeks prior to randomization. – total lymphoid irradiation or bone marrow transplantation. 3. Pregnant, planning to get pregnant, and/or lactating females or males planning to father a child within time period of the study or subsequent exclusionary period. Other protocol-defined inclusion/exclusion criteria may apply

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Novartis Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Novartis Pharmaceuticals, Study Director, Novartis Pharmaceuticals

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.